$MAIA
MAIA Biotechnology, Inc.

2023 Q1 Form 10-K Financial Statement

#000095017023009766 Filed on March 24, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.988M $1.802M $7.243M
YoY Change 45.53% 68.84%
% of Gross Profit
Research & Development $2.196M $2.393M $8.933M
YoY Change 5.71% 159.39% 155.47%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $4.184M $4.195M $16.18M
YoY Change 21.51% 415.47% 107.74%
Operating Profit -$4.184M -$16.18M
YoY Change 21.51% 107.74%
Interest Expense $5.147K -$4.530K $6.967K
YoY Change 995.11% -107.44% -100.68%
% of Operating Profit
Other Income/Expense, Net $72.19K $53.80K $412.0K
YoY Change 146.89% -104.1% -127.42%
Pretax Income -$4.117M -$4.146M -$15.80M
YoY Change 20.59% 486.27% 25.61%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$4.117M -$4.146M -$15.77M
YoY Change 20.59% 486.27% 26.12%
Net Earnings / Revenue
Basic Earnings Per Share -$0.38 -$1.75
Diluted Earnings Per Share -$0.38 -$0.38 -$1.75
COMMON SHARES
Basic Shares Outstanding 11.00M 10.95M 9.277M
Diluted Shares Outstanding 10.98M 9.277M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.586M $10.95M $10.95M
YoY Change -26.3% 3.56% 3.56%
Cash & Equivalents $0.00 $0.00
Short-Term Investments
Other Short-Term Assets $398.9K $554.3K $554.3K
YoY Change 70.0% 464.48% 464.48%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $8.334M $11.81M $11.81M
YoY Change -20.84% 10.64% 10.64%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.800K $2.800K $214.0K
YoY Change -99.69% -10.31% -67.31%
Total Long-Term Assets $740.5K $214.0K $214.0K
YoY Change -19.2% -67.31% -67.31%
TOTAL ASSETS
Total Short-Term Assets $8.334M $11.81M $11.81M
Total Long-Term Assets $740.5K $214.0K $214.0K
Total Assets $9.074M $12.02M $12.02M
YoY Change -20.71% 6.13% 6.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.127M $1.166M $1.166M
YoY Change 25.95% 21.36% 21.36%
Accrued Expenses $2.639M $2.103M $2.103M
YoY Change 85.66% 77.41% 95.79%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $3.766M $3.269M $3.269M
YoY Change 54.94% 52.33% 52.33%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $224.4K $245.3K $245.3K
YoY Change
Total Long-Term Liabilities $224.4K $245.3K $245.3K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.766M $3.269M $3.269M
Total Long-Term Liabilities $224.4K $245.3K $245.3K
Total Liabilities $3.991M $3.514M $3.514M
YoY Change 64.17% 63.76% 63.76%
SHAREHOLDERS EQUITY
Retained Earnings -$48.32M -$44.21M
YoY Change 55.45%
Common Stock $1.100K $1.096K
YoY Change 44.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.083M $8.508M $8.508M
YoY Change
Total Liabilities & Shareholders Equity $9.074M $12.02M $12.02M
YoY Change -20.71% 6.13% 6.13%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$4.117M -$4.146M -$15.77M
YoY Change 20.59% 486.27% 26.12%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$3.361M -$2.509M -$11.66M
YoY Change 32.01% 56.13% 182.71%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.474M
YoY Change -60.62%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -633.3K 12.04M
YoY Change -100.0% -151.53% -14.23%
NET CHANGE
Cash From Operating Activities -3.361M -2.509M -11.66M
Cash From Investing Activities
Cash From Financing Activities 0.000 -633.3K 12.04M
Net Change In Cash -3.365M -3.143M 376.6K
YoY Change 1116.64% 730.9% -96.2%
FREE CASH FLOW
Cash From Operating Activities -$3.361M -$2.509M -$11.66M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10996404
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201602Member
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001878313
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-41455
CY2022 dei Entity Registrant Name
EntityRegistrantName
MAIA BIOTECHNOLOGY, INC.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-1495913
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
444 West Lake Street
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1700
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Chicago
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
IL
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
06060
CY2022 dei City Area Code
CityAreaCode
312
CY2022 dei Local Phone Number
LocalPhoneNumber
416-8592
CY2022 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2022 dei Trading Symbol
TradingSymbol
MAIA
CY2022 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
0
CY2022 dei Auditor Firm
AuditorFirmId
248
CY2021 dei Auditor Firm
AuditorFirmId
274
CY2022 dei Auditor Name
AuditorName
GRANT THORNTON LLP
CY2022 dei Auditor Location
AuditorLocation
Charlotte, North Carolina
CY2021 dei Auditor Name
AuditorName
EISNERAMPER LLP
CY2021 dei Auditor Location
AuditorLocation
Iselin, New Jersey
CY2022Q4 us-gaap Cash
Cash
10950927
CY2021Q4 us-gaap Cash
Cash
10574292
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
554321
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
54537
CY2022Q4 maia Research And Development Incentives Receivable
ResearchAndDevelopmentIncentivesReceivable
302789
CY2021Q4 maia Research And Development Incentives Receivable
ResearchAndDevelopmentIncentivesReceivable
43666
CY2022Q4 us-gaap Assets Current
AssetsCurrent
11808037
CY2021Q4 us-gaap Assets Current
AssetsCurrent
10672495
CY2022Q4 us-gaap Deferred Costs
DeferredCosts
211203
CY2021Q4 us-gaap Deferred Costs
DeferredCosts
651582
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2800
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3122
CY2022Q4 us-gaap Assets
Assets
12022040
CY2021Q4 us-gaap Assets
Assets
11327199
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1165505
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
960401
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2103401
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1185595
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3268906
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2145996
CY2022Q4 maia Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
245341
CY2022Q4 us-gaap Liabilities
Liabilities
3514247
CY2021Q4 us-gaap Liabilities
Liabilities
2145996
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
70000000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.37
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9276761
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9276761
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5278435
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10955904
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10955904
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7584980
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7584980
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1096
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
758
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
52729942
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
37618438
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-44207272
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-28437993
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-15973
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
8507793
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9181203
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12022040
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11327199
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8933314
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3496796
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6143527
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4289831
CY2022 maia Ratchet Share Expense
RatchetShareExpense
1099360
CY2022 us-gaap Operating Expenses
OperatingExpenses
16176201
CY2021 us-gaap Operating Expenses
OperatingExpenses
7786627
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-16176201
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-7786627
CY2022 us-gaap Interest Expense
InterestExpense
6967
CY2021 us-gaap Interest Expense
InterestExpense
827539
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
1870
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
2012
CY2022 maia Australian Research And Development Incentives
AustralianResearchAndDevelopmentIncentives
313625
CY2021 maia Australian Research And Development Incentives
AustralianResearchAndDevelopmentIncentives
43666
CY2021 maia Gain Loss From Forgiveness Of Paycheck Protection Program Loan
GainLossFromForgivenessOfPaycheckProtectionProgramLoan
62500
CY2021 maia Change In Fair Value Of Embedded Features
ChangeInFairValueOfEmbeddedFeatures
203000
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-98394
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1546280
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2322943
CY2022 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
406922
CY2021 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-4791584
CY2022 us-gaap Profit Loss
ProfitLoss
-15769279
CY2021 us-gaap Profit Loss
ProfitLoss
-12578211
CY2021 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-74331
CY2022 maia Deemed Dividend On Warrant Modification
DeemedDividendOnWarrantModification
-450578
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16219857
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12503880
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.75
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.75
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.37
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5278435
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16219857
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12503880
CY2022 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-15973
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16235830
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12503880
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9181203
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
84000
CY2022 maia Issuance Of Common Shares Upon Exercise Of Warrants
IssuanceOfCommonSharesUponExerciseOfWarrants
385400
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2319427
CY2022 maia Issuance Of Common Shares In Connection With Equity Financing
IssuanceOfCommonSharesInConnectionWithEquityFinancing
2473560
CY2022 maia Modification Of Warrant In Equity
ModificationOfWarrantInEquity
450578
CY2022 maia Adjustments Additional Paid In Capital Deemed Dividend Modification Of Warrant
AdjustmentsAdditionalPaidInCapitalDeemedDividendModificationOfWarrant
-450578
CY2022 maia Foreign Currency Translation Adjustment
ForeignCurrencyTranslationAdjustment
-15973
CY2022 us-gaap Profit Loss
ProfitLoss
-15769279
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
8507793
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1616300
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9000
CY2021 maia Issuance Of Common Shares Upon Exercise Of Warrants
IssuanceOfCommonSharesUponExerciseOfWarrants
529425
CY2021 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
27500
CY2021 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
1
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2428935
CY2021 maia Issuance Of Stock Options To Satisfy Accrued Bonus
IssuanceOfStockOptionsToSatisfyAccruedBonus
786531
CY2021 maia Issuance Of Stock Options To Satisfy Deferred Compensation
IssuanceOfStockOptionsToSatisfyDeferredCompensation
285418
CY2021 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
11001274
CY2021 maia Stock Issued During Period Value Conversion Of Safe
StockIssuedDuringPeriodValueConversionOfSafe
25000
CY2021 maia Issuance Of Common Shares In Connection With Equity Financing
IssuanceOfCommonSharesInConnectionWithEquityFinancing
5860503
CY2021 maia Receipt Of Stock Subscription Receivable
ReceiptOfStockSubscriptionReceivable
322002
CY2021 maia Transaction Costs Incurred In Connection With Equity Financing
TransactionCostsIncurredInConnectionWithEquityFinancing
-118332
CY2021 maia Reclassification Of Warrant Liability To Equity
ReclassificationOfWarrantLiabilityToEquity
1952000
CY2021 us-gaap Profit Loss
ProfitLoss
-12578211
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9181203
CY2022 us-gaap Profit Loss
ProfitLoss
-15769279
CY2021 us-gaap Profit Loss
ProfitLoss
-12578211
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
2319427
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
2722893
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2322943
CY2021 maia Gain Loss From Forgiveness Of Paycheck Protection Program Loan
GainLossFromForgivenessOfPaycheckProtectionProgramLoan
62500
CY2021 maia Change In Fair Value Of Embedded Features
ChangeInFairValueOfEmbeddedFeatures
203000
CY2022 maia Issuance Of Ratchet Shares
IssuanceOfRatchetShares
1099360
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-98394
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1546280
CY2021 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
596953
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
505233
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
15155
CY2022 maia Increase Decrease In Deferred Offering Cost
IncreaseDecreaseInDeferredOfferingCost
-440379
CY2021 maia Increase Decrease In Deferred Offering Cost
IncreaseDecreaseInDeferredOfferingCost
651582
CY2022 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
269395
CY2022 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-322
CY2021 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
3122
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
211346
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
805516
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
915742
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
997126
CY2021 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-7037
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11655725
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4122896
CY2021 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
7369000
CY2021 maia Proceeds From Paycheck Protection Program Loan
ProceedsFromPaycheckProtectionProgramLoan
62500
CY2021 maia Proceeds From Collection Of Subscription Receivable
ProceedsFromCollectionOfSubscriptionReceivable
322002
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2473560
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5742171
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
84000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
9000
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
385400
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
529425
CY2022 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
11500000
CY2022 maia Payment Of Initial Public Offering Transaction Costs
PaymentOfInitialPublicOfferingTransactionCosts
2406170
CY2021 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
367
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12036790
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14033731
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-4430
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
376635
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9910835
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10574292
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
663457
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10950927
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10574292
CY2021 maia Conversion Of Convertible Notes And Accrued Interest Into Common Stock
ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock
8249587
CY2021 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
25000
CY2021 maia Options Issued For Accrued Bonus
OptionsIssuedForAccruedBonus
786531
CY2021 maia Options Issued For Deferred Compensation
OptionsIssuedForDeferredCompensation
285418
CY2021 maia Reclassification Of Warrant Liability To Equity
ReclassificationOfWarrantLiabilityToEquity
1952000
CY2021 maia Issuance Of Convertible Note For Payment On Loan To Officer
IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer
-21000
CY2022 maia Previously Paid Issuance Costs In Connection With The Initial Public Offering
PreviouslyPaidIssuanceCostsInConnectionWithTheInitialPublicOffering
651582
CY2022 maia Warrants Issued To Underwriters In Connection With The Initial Public Offering
WarrantsIssuedToUnderwritersInConnectionWithTheInitialPublicOffering
343735
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2018-08-03
CY2022 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
minority stockholder of THIO received one share of MAIA common stock for each share of THIO common stock owned prior to the merger.
CY2022 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
1
CY2022Q4 maia Working Capital
WorkingCapital
8539131
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-44207272
CY2022Q4 us-gaap Cash
Cash
10950927
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3268906
CY2022 us-gaap Revenues
Revenues
0
CY2022Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
263729
CY2022Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
9
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2373561
CY2022Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
11111
CY2022Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
9
CY2022Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
99999
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-44207272
CY2022Q4 us-gaap Cash
Cash
10951000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the Company’s audited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The most significant estimates in the Company’s financial statements relate to the valuation of common stock, stock options and warrants, accruals for outsourced research and development activities, and the valuation allowance of deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</span></p>
CY2021Q4 maia Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
268140
CY2021Q4 us-gaap Pension And Other Postretirement Defined Benefit Plans Current Liabilities
PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
111271
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
159269
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
41157
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2103401
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1185595
CY2022Q4 us-gaap Pension And Other Postretirement Defined Benefit Plans Current Liabilities
PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
0
CY2021Q4 us-gaap Pension And Other Postretirement Defined Benefit Plans Current Liabilities
PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
111271
CY2021Q4 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
193379
CY2022Q4 us-gaap Change In Accounting Principle Accounting Standards Update Adopted
ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
true
CY2022Q4 us-gaap Change In Accounting Principle Accounting Standards Update Adoption Date
ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
2022-01-01
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1094582
CY2021Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
384750
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
332589
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
380277
CY2022Q4 maia Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
516961
CY2021 maia Cash Paid To Settle A Portion Of Deferred Compensation Balance
CashPaidToSettleAPortionOfDeferredCompensationBalance
457749
CY2021 us-gaap Deferred Compensation Arrangement With Individual Shares Issued
DeferredCompensationArrangementWithIndividualSharesIssued
268769
CY2021 us-gaap Deferred Compensation Arrangement With Individual Fair Value Of Shares Issued
DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued
296264
CY2021Q4 us-gaap Deferred Compensation Arrangement With Individual Recorded Liability
DeferredCompensationArrangementWithIndividualRecordedLiability
743167
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1094582
CY2021Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
384750
CY2021Q2 maia Issuance Of Stock Options To Settle Accrued Bonus Balance
IssuanceOfStockOptionsToSettleAccruedBonusBalance
713536
CY2021Q2 maia Fair Value Of Stock Options Issued To Settle Accrued Bonus Balance
FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance
786531
CY2019Q3 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2021-12-31
CY2020 maia Warrant Description
WarrantDescription
In connection with each of the 2020 Convertible Notes, the Company issued each holder warrants (the 2020 Warrants) to acquire additional shares of common stock of the Company. Each holder of a 2020 Convertible Note received a warrant to purchase that number of shares of common stock as determined by multiplying the number of Equity Financing Shares which are issuable upon conversion of the holder's Convertible Note by 50%, at an exercise price equal to the conversion price per share used in the conversion of the Convertible Note.
CY2021 maia Warrant Description
WarrantDescription
In connection with each of the 2021 Convertible Notes, the Company issued each holder warrants (the 2021 Warrants) to acquire additional shares of common stock of the Company. Each holder of a 2021 Convertible Note received a warrant to purchase that number of shares of common stock as determined by multiplying the number of Equity Financing Shares which are issuable upon conversion of the holder's Convertible Note by 50%, at an exercise price equal to the conversion price per share used in the conversion of the Convertible Note.
CY2021 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
5000000
CY2021Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
8010000
CY2021 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
240000
CY2021Q3 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
1375228
CY2021Q3 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
6.00
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2300000
CY2021Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
3300000
CY2021Q4 maia Convertible Notes Outstanding
ConvertibleNotesOutstanding
0
CY2021Q3 maia Common Shares Upon Exercise Of Warrants Shares
CommonSharesUponExerciseOfWarrantsShares
686489
CY2021Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.00
CY2021 maia Warrants Exercised
WarrantsExercised
4504
CY2019Q4 maia Simple Agreement For Future Equity Issued
SimpleAgreementForFutureEquityIssued
25000
CY2019Q4 maia Percentage Of Conversion Price
PercentageOfConversionPrice
0.60
CY2021Q3 maia Simple Agreement For Future Equity Issued
SimpleAgreementForFutureEquityIssued
25000
CY2021Q3 maia Number Of Common Shares Converted Under Safe Agreement
NumberOfCommonSharesConvertedUnderSAFEAgreement
5208
CY2021Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
8.00
CY2021Q3 maia Percentage Of Conversion Price
PercentageOfConversionPrice
0.60
CY2021Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
8.00
CY2021Q3 maia Common Stock Conversion Price
CommonStockConversionPrice
4.80
CY2021 maia Change In Fair Value Of Embedded Features
ChangeInFairValueOfEmbeddedFeatures
203000
CY2022 maia Probability Percentage Of Convertible Notes Outstanding At Maturity
ProbabilityPercentageOfConvertibleNotesOutstandingAtMaturity
0
CY2022 maia Probability Percentage Of Equity Financing
ProbabilityPercentageOfEquityFinancing
1
CY2022 maia Probability Percentage Of Default Change In Control Or Dissolution
ProbabilityPercentageOfDefaultChangeInControlOrDissolution
0
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70000000
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2373561
CY2022Q1 maia Transaction Costs
TransactionCosts
0
CY2022Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
99999
CY2022Q2 maia Transaction Costs
TransactionCosts
0
CY2022Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
9.00
CY2022Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9100000
CY2022Q2 maia Warrants Exercised Shares
WarrantsExercisedShares
394501
CY2022Q2 maia Cashless Exercise At Fair Market Value Per Share
CashlessExerciseAtFairMarketValuePerShare
9.00
CY2022Q2 maia Issuance Of Common Shares Upon Cashless Exercise Of Warrants Shares
IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares
315601
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.25
CY2022Q3 us-gaap Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
2023-01-23
CY2022Q3 maia Class Of Warrant Or Right Date From Which Warrants Or Rights Expire
ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire
2027-07-27
CY2022Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
245341
CY2022 maia Class Of Warrants Issued
ClassOfWarrantsIssued
115000
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1311117
CY2021Q4 maia Class Of Warrants Weighted Average Exercise Price
ClassOfWarrantsWeightedAverageExercisePrice
4.03
CY2021 maia Class Of Warrants Weighted Average Remaining Contractual Term
ClassOfWarrantsWeightedAverageRemainingContractualTerm
P7Y3M18D
CY2022 maia Class Of Warrants Issued
ClassOfWarrantsIssued
115000
CY2022 maia Class Of Warrants Weighted Average Exercise Price Issued
ClassOfWarrantsWeightedAverageExercisePriceIssued
6.25
CY2022 maia Class Of Warrants Exercised
ClassOfWarrantsExercised
608612
CY2022 maia Class Of Warrants Weighted Average Exercise Price Exercised
ClassOfWarrantsWeightedAverageExercisePriceExercised
1.80
CY2022 maia Class Of Warrants Expired
ClassOfWarrantsExpired
20520
CY2022 maia Class Of Warrants Weighted Average Exercise Price Expired
ClassOfWarrantsWeightedAverageExercisePriceExpired
5.00
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
796985
CY2022Q4 maia Class Of Warrants Weighted Average Exercise Price
ClassOfWarrantsWeightedAverageExercisePrice
6.04
CY2022 maia Class Of Warrants Weighted Average Remaining Contractual Term
ClassOfWarrantsWeightedAverageRemainingContractualTerm
P5Y1M28D
CY2022 maia Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Percentage Of Shares Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted
0.10
CY2022 maia Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price Percentage
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage
1.10
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5797185
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.22
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M2D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
811831
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.77
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
46500
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.81
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
16888
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.82
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6545628
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.55
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M6D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
9773706
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5449715
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.24
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y7M2D
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
8804841
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15800000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-15300000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-500000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12600000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-12500000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-100000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2319427
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2722893
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
3294955
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
3013721
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1183941
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1800935
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
1499300
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
244848
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
109673
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
6724
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
102825
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
6229768
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
5027154
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
6229768
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
5027154
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1200000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2100000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.077
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.044
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.012
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.019
CY2022 maia Effective Income Tax Rate Reconciliation Loss On Extinguishment Of Debt
EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt
-0.015
CY2021 maia Effective Income Tax Rate Reconciliation Loss On Extinguishment Of Debt
EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt
-0.039
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.030
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.028
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.076
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.168
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0

Files In Submission

Name View Source Status
0000950170-23-009766-index-headers.html Edgar Link pending
0000950170-23-009766-index.html Edgar Link pending
0000950170-23-009766.txt Edgar Link pending
0000950170-23-009766-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img118615358_0.jpg Edgar Link pending
img118615358_1.jpg Edgar Link pending
img118615358_10.jpg Edgar Link pending
img118615358_11.jpg Edgar Link pending
img118615358_12.jpg Edgar Link pending
img118615358_13.jpg Edgar Link pending
img118615358_14.jpg Edgar Link pending
img118615358_15.jpg Edgar Link pending
img118615358_2.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
img118615358_3.jpg Edgar Link pending
img118615358_4.jpg Edgar Link pending
img118615358_5.jpg Edgar Link pending
img118615358_6.jpg Edgar Link pending
img118615358_7.jpg Edgar Link pending
img118615358_8.jpg Edgar Link pending
img118615358_9.jpg Edgar Link pending
maia-20221231.htm Edgar Link pending
maia-20221231.xsd Edgar Link pending
maia-ex23_1.htm Edgar Link pending
maia-ex23_2.htm Edgar Link pending
maia-ex31_1.htm Edgar Link pending
maia-ex31_2.htm Edgar Link pending
maia-ex32_1.htm Edgar Link pending
maia-ex32_2.htm Edgar Link pending
maia-ex4_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
maia-20221231_def.xml Edgar Link unprocessable
maia-20221231_lab.xml Edgar Link unprocessable
maia-20221231_pre.xml Edgar Link unprocessable
maia-20221231_htm.xml Edgar Link completed
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
maia-20221231_cal.xml Edgar Link unprocessable